Public Health Agency of Canada / Agence de santé public du Canada
Skip first menu Skip all menus Français Contact Us Help Search Canada Site
Home Centers & Labs Publications Guidelines A-Z Index
Check the help on Web Accessibility features Child Health Adult Health Seniors Health Surveillance Health Canada
Public Health Agency of Canada

 

 

Population Health Impact of Disease in Canada (PHI)

Preliminary results for cancers

 Highlights

One quarter of the impact of cancer is due to lung cancer

  • The combined impact of mortality and morbidity in Canada for cancers diagnosed 2001 is 905,000 health-adjusted life years.
  • Tne quarter of this impact is due to lung cancer.
  • Premature mortality accounts for 85% of the impact of cancers, over one quarter due to lung cancer.

Source: Population Health Impact of Disease in Canada, 2001

Notes: HALY = YLL + YERF
YLL for each age group = number of deaths X hypothetical years of life remaining
YERF for each age group = number of new cases X duration X weight for severity

data table

Morbidity for breast cancer is four times the morbidity for lung cancer

  • About 15% of the total impact of cancer is due to morbidity.
  • Morbidity for breast cancer is four times the morbidity for lung cancer because of earlier diagnosis and longer survival.

Source: Population Health Impact of Disease in Canada, 2001

Notes: Morbidity is measured by year-equivalents lost to reduced functioning (YERFs).
YERF for each age group = number of new cases X duration X weight for severity
YERFs are discounted at 3%.

data table

Smoking is a major risk factor for many cancers, but so are lack of fruit and vegetable consumption, physical inactivity, and obesity.

  • One quarter of the impact of cancer can be attributed to smoking.
  • More than one tenth can be attributed to lack of fruit and vegetable consumption.
  • The major risk factors for cancer are lifestyle risk factors and thus potentially modifiable.

Source: Population Health Impact of Disease in Canada, 2001

data table

[return to top]

How the estimates were derived

A series of health states related to cancer was identified and the effects of each were described using peer-reviewed literature and expert review. This information was used to create standardized classifications of functional limitations, a series of numbers that represent the level of severity for each of 11 attributes that span physical, mental, and social health. The Classification and Measurement System of Functional Health comprises 11 attributes with four or five levels each for this purpose.

The classification for each health state was then transformed into a global score using a statistical function. The function is based on observed values obtained from lay Canadians.

These preference scores were then integrated with epidemiologic information about the number of cases and duration of each health state related to a particular type of cancer. This provides an estimate of the morbidity, which was then combined with an estimate of mortality to calculate the total impact for each type of cancer.

This information was synthesized in structured workbooks that calculated health-adjusted life years lost for each type of cancer and the proportion of them that can be attributed to five different risk factors.

 

[return to top]

Health state descriptions and classifications

The following classifications were used in the HALY and PAF estimates. Cancers with similar prognoses or similar treatments were grouped together for purposes of classification. The durations of each health state, and the number of individuals affected, were incorporated in the subsequent step of the process. These classifications are currently being peer-reviewed.

Detailed information and related products

 

Table 1 Classification of health states related to cancer

How to read the classification

Core attribute and level

Health state

PD

PF

ES

FA

MT

SR

At diagnosis

Prognostic category

 

 

 

 

 

 

Very good prognosis

1

1

3

1

1

2

Fairly good prognosis

2

2

3

2

1

2

Poor prognosis

2

2

3

2

1

3

Metastatic disease

3

2

4

3

2

3

 

Leukemia

 

 

 

 

 

 

Chronic lymphocytic leukemia

2

2

2

2

1

2

Childhood acute lymphoblastic leukemia

2

3

3

3

1

3

Treatment

Surgery

 

 

 

 

 

 

Post-operative in-patient

2

3

3

3

1

3

Post-operative out-patient

2

2

3

2

1

2

 

Radiotherapy

 

 

 

 

 

 

Curative

3

2

3

3

1

2

Palliative

2

3

4

4

2

4

 

Chemotherapy

 

 

 

 

 

 

Mild toxicity

2

2

3

3

2

3

Moderate toxicity

2

2

3

3

2

3

Severe toxicity

2

2

3

3

2

4

 

Hormonal therapy

1

2

2

3

2

2

 

Port-surgery bone marrow transplantation

3

2

2

2

1

3

Subsequent health states

Remission

 

 

 

 

 

 

After surgery

2

2

2

2

1

3

After radiotherapy

2

2

2

3

1

2

After chemotherapy

2

2

2

2

2

2

After hormonal therapy

1

2

2

3

1

2

 

Palliative care

3

3

4

3

2

4

 

Terminal care

4

4

4

4

4

4

Summary table (continued)

Supplementary attribute and level

Health state

AN

SP

HE

VI

HF

At diagnosis

Prognostic category

 

 

 

 

 

Very good prognosis

3

1

1

1

1

Fairly good prognosis

3

1

1

1

1

Poor prognosis

3

1

1

1

1

Metastatic disease

4

1

1

1

1

 

Leukemia

 

 

 

 

 

Chronic lymphocytic leukemia

3

1

1

1

1

Childhood acute lymphoblastic leukemia

3

1

1

1

1

Treatment

Surgery

 

 

 

 

 

Post-operative in-patient

3

1

1

1

1

Post-operative out-patient

3

1

1

1

1

 

Radiotherapy

 

 

 

 

 

Curative

3

1

1

1

1

Palliative

3

1

1

1

1

 

Chemotherapy

 

 

 

 

 

Mild toxicity

3

1

1

1

1

Moderate toxicity

3

1

1

1

2

Severe toxicity

3

1

1

1

2

 

Hormonal therapy

2

1

1

1

1

 

Port-surgery bone marrow transplantation

3

1

1

1

1

Subsequent health states

Remission

 

 

 

 

 

After surgery

2

1

1

1

1

After radiotherapy

2

1

1

1

1

After chemotherapy

2

1

1

1

1

After hormonal therapy

2

1

1

1

1

 

Palliative care

3

1

1

1

3

 

Terminal care

3

1

1

1

4

Preference scores

The following preference scores were developed from these classifications. A scoring function was used to transform the classification into a single number. They are used in the calculation of the HALYs and PAFs provided in the subsequent sections.

Table 2 Preference scores for cancers

At diagnosis

Very good prognosis

0.891

Fairly good prognosis

0.853

Poor prognosis

0.809

Metastastic disease

0.439

Childhood acute lymphoblastic leukemia

0.732

Chronic lymphocytic leukemia

0.940

 

 

Treatment

Surgery in-patient

0.732

Surgery out-patient

0.853

Radiotherapy curative

0.781

Radiotherapy palliative

0.507

Chemotherapy mild toxicity

0.750

Chemotherapy moderate toxicity

0.742

Chemotherapy severe toxicity

0.706

Hormonal therapy

0.896

Bone marrow transplantation

0.864

 

 

Remission

After surgery

0.894

After radiotherapy

0.891

After chemotherapy

0.926

After hormonal therapy

0.912

 

Palliative Care

0.484

Terminal Care

0.179

[return to top]

Impact of cancer (Health-adjusted life years lost to cancers)

The following tables provide summary information for 25 types of cancer. Detailed calculations are available in an interactive Excel workbook for each cancer type. Each workbook contains several worksheets that calculate and document YLLs, YERFs, and HALYs lost to the disease for the reference year 2001.

For more information about the workbooks, or to access them:

More on workbooks
View sample workbook
Download workbooks

Table 3 Impact of cancers in Canada, 2001

Cancer

HALY YLL YERF

Oral cancer

15,896
13,458
2,438

Esophageal cancer

17,088
16,631
457

Stomach cancer

25,458
23,866
1,592

Colorectal cancer

105,217
90,438
14,779

Liver cancer

16,816
16,338
478

Gall bladder cancer

6,125
5,763
361

Pancreatic cancer

37,700
36,582
1,118

Laryngeal cancer

6,958
6,014
944

Lung cancer

220,745
212,671
8,075

Bone and connective tissue cancer

10,473
8,942
1,530

Melanoma

16,560
10,642
5,917

Non-melanoma skin cancer a

2,525
2,113
412

Breast cancer

105,896
70,425
35,471

Cervical cancer

9,814
7,319
2,494

Uterine cancer

13,218
8,038
5,179

Ovarian cancer

23,285
20,053
3,232

Prostate cancer

46,950
30,588
16,362

Bladder cancer

18,692
14,658
4,034

Kidney cancer

19,443
16,312
3,131

Brain cancer

27,399
25,288
2,111

Thyroid cancer

6,002
1,663
4,339

Non-Hodgkin's lymphoma

38,608
31,410
7,198

Hodgkin's disease

4,917
2,459
2,458

Multiple myeloma

14,221
12,843
1,378

Leukemia

29,416
27,115
2,301

All other cancers

65,647
59,158
6,490

TOTAL

905,067
770,786
134,280

Notes:
HALY = YLL + YERF
YLL for each age group = number of deaths X hypothetical years of life remaining
YERF for each age group = number of new cases X duration X weight for severity
Estimates are discounted at 3%.
a. Data for non-melanoma skin cancers are underestimated due to reporting problems.

Table 4 Impact of cancers, males, Canada, 2001

Cancer

HALY

YLL

YERF

Oral cancer

10,892

9,309

1,583

Esophageal cancer

12,473

12,139

333

Stomach cancer

14,955

13,982

972

Colorectal cancer

54,107

46,579

7,528

Liver cancer

10,651

10,342

309

Gall bladder cancer

2,375

2,226

149

Pancreatic cancer

18,746

18,206

540

Laryngeal cancer

5,499

4,735

764

Lung cancer

126,380

121,971

4,409

Bone and connective tissue cancer

5,322

4,533

789

Melanoma

9,011

6,320

2,691

Non-melanoma skin cancer a

1,604

1,438

167

Breast cancer

...

Cervical cancer

...

Uterine cancer

...

Ovarian cancer

...

Prostate cancer

46,950

30,588

16,362

Bladder cancer

13,065

10,132

2,933

Kidney cancer

11,820

9,968

1,852

Brain cancer

15,132

13,982

1,150

Thyroid cancer

1,553

625

928

Non-Hodgkin's lymphoma

21,008

17,344

3,664

Hodgkin's disease

2,809

1,475

1,335

Multiple myeloma

6,962

6,228

734

Leukemia

16,414

15,137

1,277

All other cancers

33,923

29,590

4,333

TOTAL

441,652

386,849

54,802

Notes:
HALY = YLL + YERF
YLL for each age group = number of deaths X hypothetical years of life remaining
YERF for each age group = number of new cases X duration X weight for severity
Estimates are discounted at 3%.
... not applicable
a. Data for non-melanoma skin cancers are underestimated due to reporting problems.


Table 5 Impact of cancers, females, Canada, 2001

Cancer

HALY

YLL

YERF

Oral cancer

5,004

4,149

855

Esophageal cancer

4,615

4,492

123

Stomach cancer

10,503

9,884

620

Colorectal cancer

51,111

43,859

7,251

Liver cancer

6,164

5,996

168

Gall bladder cancer

3,750

3,538

212

Pancreatic cancer

18,953

18,376

577

Laryngeal cancer

1,459

1,278

181

Lung cancer

94,365

90,700

3,665

Bone and connective tissue cancer

5,150

4,409

741

Melanoma

7,549

4,322

3,227

Non-melanoma skin cancer a

920

675

245

Breast cancer

105,896

70,425

35,471

Cervical cancer

9,814

7,319

2,494

Uterine cancer

13,218

8,038

5,179

Ovarian cancer

23,285

20,053

3,232

Prostate cancer

...

...

...

Bladder cancer

5,627

4,526

1,102

Kidney cancer

7,623

6,344

1,280

Brain cancer

12,266

11,306

960

Thyroid cancer

4,449

1,038

3,411

Non-Hodgkin's lymphoma

17,600

14,066

3,534

Hodgkin's disease

2,107

984

1,123

Multiple myeloma

7,259

6,615

644

Leukemia

13,003

11,978

1,024

All other cancers

31,724

29,568

2,157

TOTAL

463,415

383,937

79,478

Notes:
HALY = YLL + YERF
YLL for each age group = number of deaths X hypothetical years of life remaining
YERF for each age group = number of new cases X duration X weight for severity
Estimates are discounted at 3%.
... not applicable
a. Data for non-melanoma skin cancers are underestimated due to reporting problems.


Table 6 Data sources for HALYs

Data element

Source

 

Years of life lost (YLL) estimates

 

Mortality Counts

Statistics Canada, Vital Statistics: Death Database 1

Population Counts

Statistics Canada, Population estimates 0-90+ Canada - Provinces 1971-2001 2

Life Expectancies

Statistics Canada, Canadian Projected Cohort Lifetable, Lifepaths 413; Statistics Canada 4

 

Year-equivalents lost to reduced functioning (YERF) estimates

 

Preference Scores

Population Health Impact of Disease in Canada program 5

Diagnosis

Incidence: Canadian Cancer Registry (CCR) 6

 

Duration of diagnostic state: Simunovic M et al., 2001 7

Staging

Surveillance, Epidemiology, and End Results (SEER) Program 8

Treatment

Duration and distribution to treatments: Expert consultation 9

Remission

Distribution to remission states: Expert consultation 9

Case fatality

Surveillance, Epidemiology, and End Results (SEER) Program 8

Terminal and Palliative

Duration: Expert consultation 9

Survival

Surveillance, Epidemiology, and End Results (SEER) Program 8

References

  1. Health Statistics Division, Statistics Canada. Vital statistics: death database. Statistics Canada Catalogue 84F0211X.
  2. Statistics Canada, Population estimates 0-90+ Canada - Provinces 1971-2001 ( July 11, 2002 ).
  3. Based on Mortality Hazards, Canada, 2001 Cohort, from LifePaths41, Statistics Canada. http://www.statcan.ca/english/spsd/LifePaths.htm
  4. Life Tables Canada, Provinces and Territories 1995-1997, p. 10, Statistics Canada Catalogue no. 84-537
  5. Gorber S, Bernier J, McIntosh CN, Berthelot J-M. Eliciting Canadian population preferences for health states (forthcoming).
  6. Health Statistics Division, Statistics Canada. Canadian Cancer Registry.
  7. Simunovic M, Gagliardi A, McCready D, Coates A, Levine M, DePetrillo D. A snapshot of waiting times for cancer surgery provided by surgeons affiliated with regional cancer centres in Ontario. CMAJ 2001;165(4): 421-5.
  8. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence SEER 12 Regs Public Use, Nov 2002 Sub (1973 2000), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission. Using software: Surveillance Research Program, National Cancer Institute SEER*Stat software (www.seer.cancer.gov/seerstat) version 5.0.17.
  9. Expert consultation, Dr. WK Evans, Juravinski Cancer Centre, Hamilton Health Sciences and McMaster University.

[return to top]

Population attributable fraction (PAF)

Standard methods were used to attribute the health-adjusted life years lost to each type of cancer among various risk factors.

Detailed information


Table 7 Attribution to risk factors of health-adjusted life years (HALYs) lost to cancer, selected cancer sites, Canada, 2001

 

All
cancers

Breast

Colorectal

Lung

Prostate

Smoking

229,980

0

0

187,764

0

Lack of fruit and
vegetables

100,315

12,660

11,198

25,431

4,481

Physical inactivity

53,901

23,482

30,419

0

0

Obesity

40,847

8,209

12,195

0

1,647

Alcohol

18,175

5,282

0

0

0

Note:
HALY estimates are discounted at 3%.


Table 8 Data sources for population attributable fraction

Risk Factor Exposure

Tobacco (indirect method): Australia Institute of Health and Welfare, 2001b 1 based on American Cancer Society CPS II
Tobacco (direct method): General Social Survey, 1991 2
All risk factors for 2001: Canadian Community Health Survey, 2000-01 3

Relative Risks

Literature review with expert consultation 4
Alcohol: All sites except breast cancer English et al., 1995; 5 Breast cancer from Australia Institute of Health and Welfare, 2001b 1
Lack of fruit and vegetables: New Zealand Ministry of Health, 1999 6
Obesity: All sites except rectal cancer Mao Y et al., 2004; 7 Rectal cancer from Pan et al., 2002 8
Physical inactivity: Australia Institute of Health and Welfare, 2001a 3
Tobacco: Centres for Disease Control, 2002 9

References

  1. AIHW Burden of Disease. Risk factors. Last reviewed on 29 October 2001. http://www.aihw.gov.au/bod/bod_risk_factors/index.cfm.
  2. Statistics Canada, Household, Family and Social Statistics Division. General Social Survey–Health Cycle 6, 1991. Statistics Canada Survey 3894.
  3. Health Statistics Division, Statistics Canada. Canadian Community Health Survey 2000-01. Statistics Canada, Survey 3226.
  4. Flanagan W, Boswell-Purdy J, Le Petit C, Berthelot J-M. Estimating summary measures of health: a structured workbook approach. Population Health Metrics 2005; 3(1):5.
  5. English DR, Holman CDJ, Milne E. The quantification of drug caused morbidity and mortality in Australia, 1995 edition. Canberra: Commonwealth Department of Human Services and Health; 1995.
  6. New Zealand Ministry of Health (NZMOH). The health of New Zealanders 1996/7. Wellington: NZMOH; 1999.
  7. Mao Y, Pan S, Wen SW, Johnson KC; Canadian Cancer Registries Epidemiology Research Group. Physical inactivity, energy intake, obesity and the risk of rectal cancer in Canada. Int J Cancer 2003; 105(6): 831-7.
  8. Pan SY, Johnson KC, Ugnat AM, Wen SW, Mao Y; Canadian Cancer Registries Epidemiology Research Group. Association of obesity and cancer risk in Canada. Am J Epidemiol 2004; 159(3): 259-68.
  9. National Centre for Chronic Disease Prevention and Health Promotion, Centre for Disease Control. Smoking-Attributable Mortality, Morbidity and Economic Costs (SAMMEC). Based on CPS-II study (82-88). Page last updated March 18, 2002. http://apps.nccd.cdc.gov/sammec/show_risk_data.asp. Accessed October 1, 2003

 


Last Updated: 2006-10-30 Top